N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group

R. Paridaens, H. T. Mouridsen, T. Palshof, G. Cocconi, A. van Oosterom, N. Rotmensz, R. Sylvester, J. C. Heuson, M. Rozencweig

Research output: Contribution to journalArticle

Abstract

Twenty-nine evaluable patients with extensively pretreated breast cancer received PALA, a new pyrimidine antimetabolite. The drug was given by intravenous infusion over 60 min, at a daily dose of 2.5 g/m2 for 2 consecutive days. Courses were repeated at 2-week intervals and doses were escalated to toxicity. Two objective partial remissions were observed, lasting for 3 and 4.5 months respectively. Toxic effects were dose-related and consisted mainly of mucocutaneous manifestations, i.e., skin rashes, stomatitis, diarrhea, conjunctivitis and corneal ulcerations. Evidence of antitumor potential in far-advanced disease and lack of myelosuppression point to the need for additional trials of PALA in a more favorable selection of patients with breast cancer.

Original languageEnglish
Pages (from-to)67-70
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume18
Issue number1
DOIs
Publication statusPublished - 1982

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'N-(Phosphonacetyl)-l-aspartate (PALA) in advanced breast cancer: a phase II trial of the EORTC breast cancer cooperative group'. Together they form a unique fingerprint.

  • Cite this